Literature DB >> 8820192

Seroepidemiology and control of genital herpes: the value of type specific antibodies to herpes simplex virus.

M J Slomka1.   

Abstract

Herpes simplex virus (HSV) type 2 is the main cause of genital herpes infections. Conventional serological techniques cannot discriminate between antibodies specific to HSV types 1 and 2, so these methods cannot be used in the seroepidemiological investigation of genital herpes infections. The discovery of type specific antigens in HSV-1 and HSV-2, most notably glycoprotein G (gG), has been successfully exploited to develop assays for the detection of type specific HSV antibody. The presence of type specific antibodies provides evidence for infection with HSV-1, HSV-2, or both. Tests which detect humoral responses to HSV-2 have been used during the past decade to investigate populations in various countries. Most surveys of general adult populations in the developed world have found a relatively low seroprevalence of HSV-2, although this does differ between countries. Studies of HSV-2 antibody in developing countries have revealed higher rates of infection in adults. People attending sexually transmitted diseases (STD) clinics have higher rates of HSV-2 infection than general populations sampled in the same country. Assays of HSV type specific antibodies have been used in seroepidemiological surveys that include information about demography and sexual behaviour to identify risk factors for HSV-2 infection. The surveys show that people with a large number of sexual partners are at increased risk of acquiring HSV-2 infection and that a high proportion of HSV-2 infections are asymptomatic. Assays of HSV type specific antibody have been used to show that the presence of pre-existing HSV-1 antibody may reduce the severity of genital HSV-2 infection. Such assays have also been used in studies of the transmission of genital herpes. Proposed interventions to counter the spread of genital herpes include targeted education and vaccination programmes. Assays of HSV type specific antibodies may be used to monitor the effectiveness of such policies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820192

Source DB:  PubMed          Journal:  Commun Dis Rep CDR Rev        ISSN: 1350-9349


  10 in total

Review 1.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

2.  Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates.

Authors:  J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

3.  High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy.

Authors:  Craig S Miller; Joseph R Berger; Yunanan Mootoor; Sergei A Avdiushko; Hua Zhu; Richard J Kryscio
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population.

Authors:  J A Ribes; A D Steele; J P Seabolt; D J Baker
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  Comparison of a monoclonal antibody-blocking enzyme-linked immunoassay and a strip immunoblot assay for identifying type-specific herpes simplex virus type 2 serological responses.

Authors:  G J Van Doornum; M J Slomka; M Buimer; J Groen; J A Van den Hoek; I Cairo; A Vyse; D W Brown
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

6.  Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment.

Authors:  Craig S Miller; Sergei A Avdiushko; Richard J Kryscio; Robert J Danaher; Robert J Jacob
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

7.  Seropositivity and determinants of immunoglobulin-G (IgG) antibodies against Herpes simplex virus (HSV) types -1 and -2 in pregnant women in Port Harcourt, Nigeria.

Authors:  Iheanyi Omezuruike Okonko; Tochi Ifeoma Cookey
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

8.  Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood.

Authors:  Elisabeth I Laderman; Emma Whitworth; Erickson Dumaual; Mark Jones; Andrew Hudak; Wayne Hogrefe; Jim Carney; Jan Groen
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

9.  Secreted portion of glycoprotein g of herpes simplex virus type 2 is a novel antigen for type-discriminating serology.

Authors:  Staffan Görander; Bo Svennerholm; Jan-Ake Liljeqvist
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

10.  Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells.

Authors:  Elisa Crisci; Rada Ellegård; Sofia Nyström; Elin Rondahl; Lena Serrander; Tomas Bergström; Christopher Sjöwall; Kristina Eriksson; Marie Larsson
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.